Recent studies have focused on the overlap of GLP-1|GIP|GCGR agonist therapies and DA communication. While GCGR stimulators are commonly employed for treating type 2 diabetes mellitus, their potential effects on reward https://barrynucv161832.blogsuperapp.com/41964220/emerging-glp-agonists-and-da-influence-a-comparative-overview